Biologics

Here are 23 study developments in spine and orthopedic biologics for 2018 so far:

AlloSource is the world's largest processor of cellular bone allografts.

Aziyo Biologics agreed to provide its viable bone matrix product ViBone to medical device company SurGenTec for use with the GraftGun universal graft delivery system.

Cerapedics completed a $22 million financing round to accelerate commercialization of its i-FACTOR Peptide Enhanced Bone Graft for degenerative disc disease.

The global spine biologics market is forecasted to grow at a 4.4 percent compound annual growth rate to exceed $2.6 billion by 2020, according to a Market Research Engine report.

Huntington, W. Va.-based Marshall Orthopaedics surgeon Chad Lavender, MD, is now performing anterior cruciate ligament repair procedures using a patient's bone marrow.

Adipose-derived autologous stem cell therapy may be used to successfully repair a meniscus injury, according to a study in the Journal of Medical Cases.

Here are five new biologic device launches or releases in 2018 so far:

NanoFUSE Biologics will attend the 2018 International Meeting on Advanced Spine Techniques in Los Angeles between July 11 and July 14.

Global spine service company SpineMark partnered with Regenexx Corp. to refer candidates for surgery at the company's centers for excellence.